Sonoma Pharmaceuticals (NASDAQ:SNOA) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.97 and traded as high as $2.75. Sonoma Pharmaceuticals shares last traded at $2.64, with a volume of 60,402 shares traded.

Sonoma Pharmaceuticals Price Performance

The company has a market cap of $3.53 million, a price-to-earnings ratio of -0.53 and a beta of 1.41. The firm has a fifty day simple moving average of $2.76 and a 200 day simple moving average of $1.98.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.